Prospective study of evaluation to the predictive biomarker of Nivolumab by tumor tissue specimen and neighboring bronchoaveolar lavage fluid (BALF) and Blood

Not Applicable

• Conditions: previously treated patients with advanced non-small-cell lung cancer

• Registration Number: JPRN-UMIN000023822
• Lead Sponsor: Respiratory Medicine, Allergy and Rheumatic Diseases Osaka University Graduate School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-08-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

(1)With interstitial pneumonia or pulmonary fibrosis on a chest X-ray (2)Clinically significant drug allergy (3)Presencee of other active malignancy (4)With pericardial effusion, pleural effusion and ascites in need of treatment of drainage (5)Positive serum HBs antigen (6)With severe infection, cardiac diseases, diabates, hypertention, other severe complication (7)Patients received palliative radiotherapy for brain metastases and bone metastases, except for the primary lesion within 2weeks. (8)Pregnancy or lactating patients (9)The case that be judged as the inappropriate object of the this examination

Study & Design

• Study Type: Interventional
• Study Design: Not specified